4B1A

Crystal structure of lysozyme with Keggin molecule

Summary for 4B1A

• Entry DOI: 10.2210/pdb4b1a/pdb
• Descriptor: LYSOZYME C, Phosphomolybdate keggin, SODIUM ION, ... (5 entities in total)
• Functional Keywords: hydrolase, corm
• Biological source: GALLUS GALLUS (CHICKEN)
• Total number of polymer chains: 1
• Total formula weight: 16211.83

Authors

Mukhopadhyay, A.,Silva, T.S.,Romao, M.J.,Romao, C.C. (deposition date: 2012-07-09, release date: 2013-02-06, Last modification date: 2024-11-06)

Primary citation

Seixas, J.D.,Mukhopadhyay, A.,Santos-Silva, T.,Otterbein, L.E.,Gallo, D.J.,Rodrigues, S.S.,Guerreiro, B.H.,Goncalves, A.M.,Penacho, N.,Marques, A.R.,Coelho, A.C.,Reis, P.M.,Romao, M.J.,Romao, C.C.
Characterization of a Versatile Organometallic Pro-Drug (Corm) for Experimental Co Based Therapeutics.
Dalton Trans, 42:5985-, 2013

PubMed Abstract: The complex fac-[Mo(CO)(3)(histidinate)]Na has been reported to be an effective CO-Releasing Molecule in vivo, eliciting therapeutic effects in several animal models of disease. The CO releasing profile of this complex in different settings both in vitro and in vivo reveals that the compound can readily liberate all of its three CO equivalents under biological conditions. The compound has low toxicity and cytotoxicity and is not hemolytic. CO release is accompanied by a decrease in arterial blood pressure following administration in vivo. We studied its behavior in solution and upon the interaction with proteins. Reactive oxygen species (ROS) generation upon exposure to air and polyoxomolybdate formation in soaks with lysozyme crystals were observed as processes ensuing from the decomposition of the complex and the release of CO.

PubMed: 23223860
DOI: 10.1039/C2DT32174B

Experimental method

X-RAY DIFFRACTION (1.67 Å)